Adenosine receptors as therapeutic targets
Open accessThe DOI matches its Crossref record; 215 of the 215 references it cites were found in a registry or an index.
Abstract
Adenosine receptors are major targets of caffeine, the most commonly consumed drug in the world. There is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cerebral and cardiac ischaemic diseases, sleep disorders, immune and inflammatory disorders and cancer. After more than three decades of medicinal chemistry research, a considerable number of selective agonists and antagonists of adenosine receptors have been discovered, and some have been clinically evaluated, although none has yet received regulatory approval. However, recent advances in the understanding of the roles of the various adenosine receptor subtypes, and in the development of selective and potent ligands, as discussed in this review, have brought the goal of therapeutic application of adenosine receptor modulators considerably closer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among these, A1 and A2A receptors are considered the principal targets mediating caffeine’s physiological effects.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“A key mechanism underlying the interaction between caffeine and exercise is caffeine’s pharmacological action as a competitive adenosine receptor antagonist.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“Instead, competitive blockade of A1 and A2A adenosine receptors is widely regarded as the central mechanism underlying caffeine’s physiological effects during both habitual intake and exercise (Figure 1) [28,29,30,31].”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“Within the range of plasma concentrations relevant to sports nutrition practice, typically micromolar levels achieved after low-to-moderate caffeine intake, caffeine’s primary mechanism of action is unlikely to involve phosphodiesterase (PDE) inhibition or direct intracellular Ca2+ release.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [29]
In the citing paper
“This effect modulates key physiological processes such as anti-inflammatory responses, angiogenesis, and vasodilation, as illustrated in Figure 2 (left panel) [52,66,67,68].”
From Comparison of Polynucleotide and Polydeoxyribonucleotide in Dermatology: Molecular Mechanisms and Clinical Perspectives (2025) · cites this paper as [68]
Citations
Cites
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors
Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K.-N., & Linden, J. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01511-4 · Cited by 2,585
Self-citationCalker, D. V., Müller, M., & Hamprecht, B. (1979) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1979.tb05236.x · Cited by 1,371
Ohta, A., & Sitkovsky, M. (2001) · Nature · doi:10.1038/414916a · Cited by 1,334
Astrocytic Purinergic Signaling Coordinates Synaptic Networks
Pascual, O., Casper, K. B., Kubera, C., Zhang, J., Revilla-Sanchez, R., Sul, J.-Y., Takano, H., Moss, S. J., McCarthy, K., & Haydon, P. G. (2005) · Science · doi:10.1126/science.1116916 · Cited by 1,280
Adenosine: A Mediator of the Sleep-Inducing Effects of Prolonged Wakefulness
Porkka-Heiskanen, T., Strecker, R. E., Thakkar, M., Bjørkum, A. A., Greene, R. W., & McCarley, R. W. (1997) · Science · doi:10.1126/science.276.5316.1265 · Cited by 1,252
Subclasses of external adenosine receptors.
Londos, C., Cooper, D. M., & Wolff, J. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.5.2551 · Cited by 1,081
Extracellular metabolism of ATP and other nucleotides
Zimmermann, H. (2000) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s002100000309 · Cited by 990
Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor
Ledent, C., Vaugeois, J.-M., Schiffmann, S. N., Pedrazzini, T., Yacoubi, M. E., Vanderhaeghen, J.-J., Costentin, J., Heath, J. K., Vassart, G., & Parmentier, M. (1997) · Nature · doi:10.1038/41771 · Cited by 918
Adenosine: an endogenous regulator of innate immunity
Haskó, G. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.11.003 · Cited by 899
Research works printed but not linked: 1
- Ji, X. D. & Jacobson, K. A. [3H]-ZM241385 as a radioligand at recombinant human A2B adenosine receptors. Drug Des. Discov. 16, 217–226 (1999).
Cited by
Items 601–700 of 1,001
Guzmán‐Gutiérrez, E., Abarzua, F., Belmar, C., Nien, J. K., Ramírez, M. A., Arroyo, P., Salomón, C., Westermeier, F., Puebla, C., Leiva, A., et al. (2011) · Current Vascular Pharmacology · doi:10.2174/157016111797484062 · Cited by 28
“MRS1523 >10000 3660 19 CHO [100]”
InfluentialEctonucleotidase inhibitors: a patent review (2011-2016)
al‐Rashida, M., Qazi, S. U., Batool, N., Hameed, A., & Iqbal, J. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1369958 · Cited by 26
The CD73/Ado System—A New Player in RT Induced Adverse Late Effects
de Leve, S., Wirsdörfer, F., & Jendrossek, V. (2019) · Cancers · doi:10.3390/cancers11101578 · Cited by 28
Exploiting the Indole Scaffold to Design Compounds Binding to Different Pharmacological Targets
Taliani, S., Settimo, F. D., Martini, C., Laneri, S., Novellino, E., & Greco, G. (2020) · Molecules · doi:10.3390/molecules25102331 · Cited by 27
“Being ubiquit usly distributed in tissues and organs of mammalians, ARs have been considered attractive targets for the development f agonist- and antagonist-based th rapies against wide range of pathologi s, including CNS disorders, cardiac arrhythmia, ischemic injuries, asthma, renal fai ure and inflammatory disease…”
BackgroundCytotoxic purine nucleoside analogues bind to A1, A2A, and A3 adenosine receptors
Jensen, K., Johnson, L. A., Jacobson, P. A., Kachler, S., Kirstein, M. N., Lamba, J. K., & Klotz, K. (2012) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-011-0719-6 · Cited by 26
“These biologic processes are primarily mediated through the seventransmembrane G-protein-coupled adenosine receptors which include A1, A2A, A2B, and A3 receptor subtypes occurring in a tissue-specific manner (Fredholm et al. 2005; Jacobson and Gao 2006; Ralevic and Burnstock 1998).”
Mallok, A., Vaillant, J. D., Soto, M. T. D., Viebahn-Hänsler, R., Viart, M. D. L. Á. B., Pérez, Á. F., Cedeño, R. I. D., & Fernández, O. (2014) · Neurological Research · doi:10.1179/1743132814y.0000000445 · Cited by 28
Dobrachinski, F., Gerbatin, R. R., Sartori, G., Marques, N. F., Zemolin, A. P. P., Silva, L. F. A., Franco, J. L., Royes, L. F. F., Fighera, M. R., & Soares, F. A. A. (2016) · Journal of Neurotrauma · doi:10.1089/neu.2016.4563 · Cited by 25
“43,58,59 In addition, modulation of glutamate uptake and regulation of glutamate transporters activity/expression are linked to the PI3K pathway, 65,66 which is modulated by A 1 .”
Zeilinger, M., Pichler, F., Nics, L., Wadsak, W., Spreitzer, H., Hacker, M., & Mitterhauser, M. (2017) · EJNMMI Research · doi:10.1186/s13550-016-0249-9 · Cited by 27
P1 Receptor Agonists/Antagonists in Clinical Trials - Potential Drug Candidates of the Future
Borah, P., Deka, S., Mailavaram, R. P., & Deb, P. K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190716111245 · Cited by 29
Adenosine restrains ILC2-driven allergic airway inflammation via A2A receptor
Xiao, Q., Han, X., Liu, G., Zhou, D., Zhang, L., He, J., Xu, H., Zhou, P., Yang, Q., Chen, J., et al. (2021) · Mucosal Immunology · doi:10.1038/s41385-021-00475-7 · Cited by 26
Coppi, E., Cherchi, F., Venturini, M., Lucarini, E., Corradetti, R., Mannelli, L. D. C., Ghelardini, C., Pedata, F., & Pugliese, A. M. (2022) · Molecules · doi:10.3390/molecules27061890 · Cited by 29
“Furthermore, we extended the results to a newly synthetized BAY60-6583 analog, the A2BR-selective agonist P453, recently described in [43], which proved to have higher affinity than BAY60-6583 [42].”
BackgroundResultHypoxia induces cardiac malformations via A1 adenosine receptor activation in chicken embryos
Ghatpande, S. K., Billington, C. J., Rivkees, S. A., & Wendler, C. C. (2008) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.20438 · Cited by 25
“Four types of adenosine receptors are known: A1 and A3 adenosine receptors inhibit adenylyl cyclase activity, and A2a and A2b receptors stimulate adenylyl cylase activity (Jacobson and Gao, 2006; Olah and Stiles, 1995).”
BackgroundFerrante, A., Martire, A., Pepponi, R., Varani, K., Vincenzi, F., Ferraro, L., Beggiato, S., Tebano, M. T., & Popoli, P. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.08.013 · Cited by 30
McNeely, P. M., Naranjo, A. N., & Robinson, A. S. (2012) · Biotechnology Journal · doi:10.1002/biot.201200076 · Cited by 29
“This receptor subfamily alone has been proposed as targets in treatments for ischemia, neurodegenerative disorders, cancer, and diabetes [5], among other conditions.”
Lee, J. S., & Yilmaz, Ö. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010199 · Cited by 25
“This will further result in elevated cAMP formation via adenylate cyclase activity and subsequent activation of protein kinase A (PKA) and cAMP response element (CRE)-mediated gene expression that are shown to non-redundantly downregulate inflammation [18].”
BackgroundZałuski, M., Schabikowski, J., Schlenk, M., Olejarz‐Maciej, A., Kubas, B., Karcz, T. P., Kuder, K., Latacz, G., Zygmunt, M., Synak, D., et al. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.004 · Cited by 25
Pafundo, D. E., Alvarez, C. L., Krumschnabel, G., & Schwarzbaum, P. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.078246 · Cited by 25
Therapeutic potential of adenosine receptor antagonists and agonists
Press, N. J., Gessi, S., Borea, P. A., & Polosa, R. (2007) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.17.8.979 · Cited by 27
“With the combination of pharmacological data, using selective ligands and genetically modified mice, important progress has been made toward an understanding of the role of ARs in a variety of diseases [19] , such as inflammatory conditions [20,21] , heart attack [22] , ischaemia–reperfusion injury [23] , vascular inj…”
BackgroundCholinergic and Adenosinergic Modulation of Synaptic Release
Yang, D., Ding, C., Qi, G., & Feldmeyer, D. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2020.06.006 · Cited by 24
“As mentioned above, there are four subtypes of adenosine receptors, the A1, A2A, A2B, and A3 adenosine receptors (A1AR, A2AAR, A2BAR, A3AR) that display distinct tissue distribution, pharmacological characteristics and down-stream cellular signal transduction mechanisms (Dunwiddie and Masino, 2001; Jacobson and Gao, 2…”
Therapeutic potential of adenosine receptor modulators in cancer treatment
Maity, P., Ganguly, S., & Deb, P. K. (2025) · RSC Advances · doi:10.1039/d5ra02235e · Cited by 26
Baumgartner, C., Eberle, C., Diederich, F., Lauw, S., Rohdich, F., Eisenreich, W., & Bacher, A. (2007) · Helvetica Chimica Acta · doi:10.1002/hlca.200790105 · Cited by 24
Adenosine A 3 Receptor: A promising therapeutic target in cardiovascular disease
Nishat, S., Khan, L. A., Ansari, Z. M., & Basir, S. F. (2016) · Current Cardiology Reviews · doi:10.2174/1573403x12666160111125116 · Cited by 24
“The presence of an additional 2-chloro substituent in Cl-IB-MECA makes it more selective than IB-MECA [6].”
BackgroundMethodInfluentialShakya, A. K., Naik, R. R., Almasri, I. M., & Kaur, A. P. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190716145206 · Cited by 25
Tan, L., Wang, Y., Yu, J., Wang, R., Zu, J., & Tan, R. (2020) · ACS Omega · doi:10.1021/acsomega.0c02502 · Cited by 26
Deng, J. P., Zhang, B., Chu, H., Wang, X., Wang, Y., Gong, H., Li, R., Yang, D., Li, C., Dou, Y., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103505 · Cited by 24
“The immune modulatory characteristics of adenosine are attributed to its four trans-membrane receptors: A1, A2A, A2B, and A3 [32].”
Purinergic receptors modulators: An emerging pharmacological tool for disease management
Mahmood, A., & Iqbal, J. (2022) · Medicinal Research Reviews · doi:10.1002/med.21888 · Cited by 28
“Extracellular adenosine serves a cytoprotective role under stress for organs or tissue in various physiological and pathophysiological conditions.(14,15) This cytoprotective response results from angiogenesis or vasodilation,(16) suppression of inflammation,(17,18) and ischemic preconditioning in the brain, heart, and…”
BackgroundYadav, V., Nayeem, M. A., Tilley, S. L., & Mustafa, S. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13265 · Cited by 25
“Adenosine receptors are present on endothelium as well as smooth muscle cells of arteries (Ohisalo, 1987; Mubagwa et al., 1996; Mubagwa and Flameng, 2001; Jacobson and Gao, 2006; Hein et al., 2013).”
BackgroundAdenosine Receptor Ligands and PET Imaging of the CNS
Bauer, A., & Ishiwata, K. (2009) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-89615-9_19 · Cited by 27
“It will, therefore, aid in stratifying the process of evaluating promising therapeutic compounds from bench to market, and it has also the potential to evolve into a useful diagnostic tool of adenosine-related diseases, particularly, neurodegenerative disorders [e.g., Parkinson’s disease (PD) and Alzheimer’s disease (…”
BackgroundMichielan, L., Bolcato, C., Federico, S., Cacciari, B., Bacilieri, M., Klotz, K., Kachler, S., Pastorin, G., Cardin, R., Sperduti, A., et al. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.05.038 · Cited by 24
Deletion of CD73 promotes dyslipidemia and intramyocellular lipid accumulation in muscle of mice
Burghoff, S., Flögel, U., Bongardt, S., Burkart, V., Sell, H., Tucci, S., Ikels, K., Eberhard, D., Kern, M., Klöting, N., et al. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2012.755547 · Cited by 24
Squarcialupi, L., Colotta, V., Catarzi, D., Varano, F., Betti, M., Varani, K., Vincenzi, F., Borea, P. A., Porta, N., Ciancetta, A., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.060 · Cited by 24
Luciferase-Based Assay for Adenosine: Application toS-Adenosyl- l -homocysteine Hydrolase
Burgos, E. S., Gulab, S. A., Cassera, M. B., & Schramm, V. L. (2012) · Analytical Chemistry · doi:10.1021/ac203297z · Cited by 24
Yang, G. K., Fredholm, B. B., Kieffer, T. J., & Kwok, Y. N. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00050.2012 · Cited by 24
Tosolini, M., Pont, F., Bétous, D., Ravet, E., Ligat, L., Lopez, F., Poupot, M., Poirot, M., Pérouzel, É., Tiraby, G., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01204-14 · Cited by 26
“Stimulation of the active conformation triggers G s activation of adenylate cyclase to produce cAMP, which then propagates downstream signaling (17).”
BackgroundInfluentialCEC of phytochemical bioactive compounds
Yang, F. Q., Zhao, J., & Li, S. (2009) · Electrophoresis · doi:10.1002/elps.200900570 · Cited by 24
Fragment-Based Discovery of Subtype-Selective Adenosine Receptor Ligands from Homology Models
Ranganathan, A., Stoddart, L. A., Hill, S. J., & Carlsson, J. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01120 · Cited by 26
AMP-guided tumour-specific nanoparticle delivery via adenosine A1 receptor
Dai, T., Li, N., Han, F., Zhang, H., Zhang, Y., & Liu, Q. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.01.011 · Cited by 25
Equilibrium and kinetic selectivity profiling on the human adenosine receptors
Guo, D. M., Dijksteel, G. S., van Duijl, T. T., Heezen, M. R., Heitman, L. H., & IJzerman, A. P. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.02.018 · Cited by 25
α,α′-N-Boc-Substituted Bi- and Terthiophenes: Fluorescent Precursors for Functional Materials
Dong, Y., Navarathne, D., Bolduc, A., McGregor, N. G. S., & Skene, W. G. (2012) · The Journal of Organic Chemistry · doi:10.1021/jo300687d · Cited by 24
Gao, X., Wang, Y., Liu, Y., Yue, Q., Liu, Z., Ke, M., Zhao, S., & Li, C. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16656198 · Cited by 25
“In the four subtypes of ARs, A2AR shows important physiological functions such as regulating blood flow and anti-inflammation.(20) In previous work, we developed a series of A2AR nanoagonist (NA), in which multiple copies of agonistic agents were labeled on PAMAM dendrimer as a nano-scaffold.”
BackgroundChen, J., Chen, G., Cheng, C., Cong, Y., Li, X., & Zhao, H. (2017) · The Journal of Chemical Thermodynamics · doi:10.1016/j.jct.2017.07.023 · Cited by 24
Deganutti, G., Zhukov, A., Deflorian, F., Federico, S., Spalluto, G., Cooke, R. M., Moro, S., Mason, J. S., & Bortolato, A. (2017) · In Silico Pharmacology · doi:10.1007/s40203-017-0037-x · Cited by 25
Species differences and mechanism of action of A3 adenosine receptor allosteric modulators
Du, L., Gao, Z.-G., Paoletta, S., Wan, T. C., Gizewski, E. T., Barbour, S., van Veldhoven, J. P. D., IJzerman, A. P., Jacobson, K. A., & Auchampach, J. A. (2017) · Purinergic Signalling · doi:10.1007/s11302-017-9592-1 · Cited by 24
Self-citation8-Bromination of 2,6,9-trisubstituted purines with pyridinium tribromide
Bliman, D., Pettersson, M., Bood, M., & Grøtli, M. (2014) · Tetrahedron Letters · doi:10.1016/j.tetlet.2014.03.084 · Cited by 24
Tourneur, L., Mistou, S., Schmitt, A., & Chiocchia, G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802263200 · Cited by 24
Design and application of locally delivered agonists of the adenosine A2Areceptor
Mantell, S. J., Jones, R., & Trevethick, M. (2009) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.09.57 · Cited by 24
Tuccinardi, T., Schenone, S., Bondavalli, F., Brullo, C., Bruno, O., Mosti, L., Zizzari, A. T., Tintori, C., Manetti, F., Ciampi, O., et al. (2008) · ChemMedChem · doi:10.1002/cmdc.200700355 · Cited by 23
Marin, R. M., Franchini, K. G., & Rocco, S. A. (2007) · Journal of Separation Science · doi:10.1002/jssc.200700194 · Cited by 24
Vega, J. L., Puebla, C., Vásquez, R., Farías, M., Alarcón, J., Pastor‐Anglada, M., Krause, B. J., Casanello, P. C., & Sobrevía, L. (2009) · Cardiovascular Research · doi:10.1093/cvr/cvp045 · Cited by 24
A2Badenosine receptor antagonists and their potential indications
Zablocki, J. A., Elzein, E. O., & Kalla, R. V. (2006) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.16.10.1347 · Cited by 24
“As the potential indications of A2B AdoR have been described in detail elsewhere [2-6], the major indications will only be mentioned briefly to demonstrate the potential utility of A2B AdoR antagonists.”
BackgroundAdenosine Receptors in Neuroinflammation and Neurodegeneration
Salmaso, V., Menin, S., Moro, S., Spalluto, G., & Federico, S. (2025) · Cells · doi:10.3390/cells14201585 · Cited by 27
“In cardiac muscles and neurons, A 1 AR can activate pertussis toxin-sensitive and K ATP potassium ion channels and inactivate Q, P, and N-type calcium channels, influencing excitability [28].”
Positive allosteric modulation of the adenosine A2a receptor attenuates inflammation
Welihinda, A. A., & Amento, E. P. (2014) · Journal of Inflammation · doi:10.1186/s12950-014-0037-0 · Cited by 23
“Selective orthosteric agonism at the A2aR as a therapeutic strategy has been extensively studied using high affinity agonists for over three decades [30,31].”
BackgroundMathew, S. C., By, Y., Berthault, A., Virolleaud, M., Carrega, L., Chouraqui, G., Comméiras, L., Condo, J., Attolini, M. M., Gaudel‐Siri, A., et al. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/c0ob00017e · Cited by 23
Moré, A. O. O., Cidral‐Filho, F. J., Mazzardo‐Martins, L., Martins, D. F., do Nascimento, F. P., Li, S. M., & Santos, A. R. S. (2013) · Journal of Caffeine Research · doi:10.1089/jcr.2013.0014 · Cited by 24
“However, adenosine or caffeine administration can produce either analgesic or pronociceptive effects depending on many variables, including dose, administration site, and the modality of pain treated.(5,35,36) This duality observed in the effects of adenosine and caffeine in pain conditions may be related to the expre…”
BackgroundPharmacology of the Adenosine A3 Receptor in the Vasculature and Essential Hypertension
Ho, M., Low, L. M., & Rose’Meyer, R. B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150021 · Cited by 27
“Adenosine A3 receptor selective agonists have been reported to stimulate cardiac preconditioning through activation of the KATP channels and stimulation of the RhoA-phospholipase D1 signalling pathways [14].”
BackgroundAkbarzadeh, A. R., & Dekamin, M. G. (2017) · Green Chemistry Letters and Reviews · doi:10.1080/17518253.2017.1380234 · Cited by 23
Astrocytes: Stars of the Sacred Disease
Binder, D. K. (2018) · Epiliepsy currents/Epilepsy currents · doi:10.5698/1535-7597.18.3.172 · Cited by 24
Adenosine in the Inflamed Gut: A Janus Faced Compound
Estrela, A. B., & Abraham, W. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711796011274 · Cited by 23
“de phosphoinositide 3-kinase (PI3K), protein kinase B (PKB or Akt) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF- B)-mediated gene regulation [5].”
BackgroundNoise-induced hearing loss in the 21stcentury: A research and translational update
Wong, A. C. Y. (2013) · World Journal of Otorhinolaryngology · doi:10.5319/wjo.v3.i3.58 · Cited by 24
Auchampach, J. A., Gizewski, E. T., Wan, T. C., de Castro, S., Brown, G. G., & Jacobson, K. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.11.009 · Cited by 23
“Modulation of the A3 adenosine receptor (A3AR) is being explored in preclinical and clinical studies for the treatment of a variety of diseases [1,2].”
BackgroundSelf-citationNeutrophil–Endothelial Cell Interactions
Filep, J. G., & Colgan, S. P. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9781139195737.013 · Cited by 24
Hyaluronate Increases Polynucleotides Effect on Human Cultured Fibroblasts
Guizzardi, S., Uggeri, J., Belletti, S., & Cattarini, G. (2013) · Journal of Cosmetics, Dermatological Sciences and Applications · doi:10.4236/jcdsa.2013.31019 · Cited by 22
“[11-13].”
Bharate, S. B., Singh, B., Kachler, S., de Oliveira, A. L. N., Kumar, V., Bharate, S. S., Vishwakarma, R. A., Klotz, K., & Gutiérrez‐de‐Terán, H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00552 · Cited by 22
Optogenetic stimulus-triggered acquisition of seizure resistance
Shimoda, Y., Beppu, K., Ikoma, Y., Morizawa, Y. M., Zuguchi, S., Hino, U., Yano, R., Sugiura, Y., Moritoh, S., Fukazawa, Y., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105602 · Cited by 21
“Especially, adenosine is known to have a strong anti-convulsant effect that can contribute to seizure termination (Dragunow et al., 1985; Jacobson and Gao, 2006; Van Gompel et al., 2014; Young and Dragunow, 1994).”
BackgroundA purine derivative, paraxanthine, promotes cysteine uptake for glutathione synthesis
Matsumura, N., Kinoshita, C., Bhadhprasit, W., Nakaki, T., & Aoyama, K. (2022) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2022.11.001 · Cited by 22
Small molecule allosteric modulation of the adenosine A1 receptor
Nguyen, A. T. N., Tran, Q. L., Baltos, J., McNeill, S. M., Nguyen, D. T. N., & May, L. T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1184360 · Cited by 24
Preliminary SAR analysis of novel antiproliferative N6,5′-bis-ureidoadenosine derivatives
Peterson, M. A., Oliveira, M. D. M., Christiansen, M. A., & Cutler, C. E. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.09.083 · Cited by 22
Ben, D. D., Buccioni, M., Lambertucci, C., Kachler, S., Falgner, N., Marucci, G., Thomas, A., Cristalli, G., Volpini, R., & Klotz, K. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.10.011 · Cited by 22
“These data make A3AR an attractive therapeutic target and the design and synthesis of potent and selective agonists for this adenosine receptor (AR) subtype could be helpful to provide tools for further characterization and evaluation of the physio-pathological role of the protein and for the development of new drugs…”
MethodEmerging role of extracellular nucleotides and adenosine in multiple sclerosis
Cieślak, M., Kukulski, F., & Komoszyński, M. (2011) · Purinergic Signalling · doi:10.1007/s11302-011-9250-y · Cited by 27
“express P1 receptors, namely A1, A2A, A2B, and A3, that are activated by extracellular adenosine [12, 13].”
BackgroundGuo, M., Gao, Z., Tyler, R., Stodden, T., Li, Y., Ramsey, J., Zhao, W., Wang, G., Wiers, C. E., Fowler, J. S., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01009 · Cited by 22
Self-citationAlarcón, S., Toro, M. D. L. Á., Villarreal, C., Melo, R., Fernández-Gajardo, R., Ayuso‐Sacido, Á., Uribe, D., Martín, R. S., & Quezada, C. (2020) · Cells · doi:10.3390/cells9081914 · Cited by 23
Michael, S., Warstat, C., Michel, F., Yan, L., Müller, C. E., & Nieber, K. (2009) · Purinergic Signalling · doi:10.1007/s11302-009-9174-y · Cited by 22
“Adenosine binds to four different types of G proteincoupled cell surface receptors referred to as A1R, A2AR, A2BR and A3R, each of which has a unique pharmacological profile, tissue distribution and signalling pathway [18].”
BackgroundRobillard, K. R., Bone, D. B. J., & Hammond, J. R. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.10.002 · Cited by 22
Adenosine modulates oesophageal sensorimotor function in humans
Remes-Troche, J. M., Chahal, P. S., Mudipalli, R. S., & Rao, S. S. C. (2008) · Gut · doi:10.1136/gut.2006.116699 · Cited by 22
Hinze, A. V., Mayer, P., Harst, A., & von Kügelgen, I. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.08.003 · Cited by 22
“The two A3 receptor selective antagonists MRS1523 (10–300 nM) and VUF 5574 (1–100 nM) [20] blocked the increases in expression of EGR2 and EGR3 induced by 2-choro-IB-MECA (Fig.”
BackgroundMethodResultInfluentialA new synthesis of 2,8-disubstituted pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines
Dolzhenko, A. V., Pastorin, G., Dolzhenko, A. V., & Chui, W. K. (2009) · Tetrahedron Letters · doi:10.1016/j.tetlet.2009.07.113 · Cited by 22
Kim, S. Y., Seo, M., Oh, J., Cho, E.-A., & Juhnn, Y. (2007) · Experimental & Molecular Medicine · doi:10.1038/emm.2007.64 · Cited by 22
“Adenosine receptors are major targets of caffeine, and there is growing evidence that they could also be promising therapeutic targets in a wide range of conditions, including cancer (Jacobson and Gao, 2006).”
The Xenometabolome of Early-Life Stage Salmonids Exposed to 6PPD-Quinone
Ankley, P. J., da Silva, F. C., Hunnie, B., Roberts, C., Eriksson, A. N. M., Kohlman, E., Corker, J., Westcott, J., Germain, B., Martin, M. J., et al. (2025) · Environmental Science & Technology · doi:10.1021/acs.est.5c01442 · Cited by 26
Azuaje, F. J., Devaux, Y., & Wagner, D. R. (2010) · Biosystems · doi:10.1016/j.biosystems.2010.01.002 · Cited by 24
Quantitative prediction of selectivity between the A1 and A2A adenosine receptors
Burggraaff, L., van Vlijmen, H., IJzerman, A. P., & van Westen, G. J. P. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00438-3 · Cited by 22
Lin, C., Batista, D. D. G. J., Mazzeti, A. L., Girão, R. D., de Oliveira, G. M., Karalić, I., Hulpia, F., Soeiro, M. D. N. C., Maes, L. J. R. M., Caljon, G., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114165 · Cited by 21
High ligand efficiency quinazoline compounds as novel A2A adenosine receptor antagonists
Bolteau, R., Duroux, R., Laversin, A., Vreulz, B., Shiriaeva, A., Stauch, B., Han, G. W., Cherezov, V., Renault, N., Barczyk, A., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114620 · Cited by 21
Orlans, J., Rose, S. L., Ferguson, G., Oscarsson, M., Puron, A. H., Beteva, A., Debionne, S., Theveneau, P., Coquelle, N., Kieffer, J., et al. (2025) · Communications Chemistry · doi:10.1038/s42004-024-01404-y · Cited by 27
“The A 2A R receptor is involved in a variety of physiopathological and neurological disorders, such as Parkinson's disease, Pain, in fl ammation and cancer and represents, consequently, an important target for drug discovery 47,48 .”
Yip, K. H., Lau, H. Y. A., & Wise, H. M. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01446.x · Cited by 21
“Adenosine exerts its cellular effects through four distinct subtypes of adenosine receptor (AR), namely A1, A2A, A2B and A3, which belong to the GPCR family (Jacobson and Gao, 2006; Spicuzza et al., 2006).”
BackgroundInfluentialBrito, R., Pereira, M. R., Paes‐de‐Carvalho, R., & Calaza, K. D. C. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07909.x · Cited by 27
Rebuilding immunity in cancer patients
Vuk‐Pavlović, S. (2007) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2007.06.025 · Cited by 21
“Interestingly, caffeine is an antagonist of adenosine (66); it is tempting to speculate that the reason coffee drinkers are less prone to gastrointestinal cancers (67) stems from the caffeine function as an adenosine antagonist.”
BackgroundTreatment with Adenosine Receptor Agonist Ameliorates Pain Induced by Acute and Chronic Inflammation
Montes, G. C., Hammes, N., da Rocha, M. D., Montagnoli, T. L., Fraga, C. A. M., Barreiro, E. J., Sudo, R. T., & Zapata‐Sudo, G. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.231241 · Cited by 21
“This in turn leads to inhibition of the formation and release of proinflammatory cytokines such as TNF-a and IL-1b (Jacobson and Gao, 2006; Varani et al., 2010; Chen et al., 2013), and it also leads to inhibition nuclear factor-kB nuclear translocation (Mediero et al., 2013).”
BackgroundThe endocannabinoid system, a novel and key participant in acupuncture’s multiple beneficial effects
Hu, B., Bai, F., Xiong, L., & Wang, Q. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.04.006 · Cited by 23
“It is commonly stated that A1 and A3 are inhibitory receptors and that A2A and A2B are stimulatory receptors (Fredholm et al., 2005a; Jacobson and Gao, 2006).”
Kanda, T., & Jenner, P. G. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.09.026 · Cited by 21
Adenosine receptors as promising targets for the management of ocular diseases
Spinozzi, E., Baldassarri, C., Acquaticci, L., Bello, F. D., Grifantini, M., Cappellacci, L., & Petrelli, R. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-021-02704-x · Cited by 26
Eastwood, P. R., González, J., Paredes, S., Fonquerna, S., Cardús, A., Alonso, J. A., Nueda, A., Domènech, T., Reinoso, R. F., & Vidal, B. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.077 · Cited by 21
Michielan, L., Federico, S., Terfloth, L., Hristozov, D., Cacciari, B., Klotz, K., Spalluto, G., Gasteiger, J., & Moro, S. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci900311j · Cited by 21
Temporini, C., Massolini, G., Marucci, G., Lambertucci, C., Buccioni, M., Volpini, R., & Calleri, E. (2012) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-012-6353-4 · Cited by 21
The role of dinucleoside polyphosphates on the ocular surface and other eye structures
Carracedo, G., Crooke, A., Guzmán‐Aránguez, A., de Lara, M. J. P., Martín‐Gil, A., & Pintor, J. J. (2016) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2016.07.001 · Cited by 21
“Consequently, AMP is converted into the nucleoside adenosine, which mediates purinergic effects via P1 receptors interaction (Jacobson and Gao, 2006).”
BackgroundThe Anti-Cancer Effect of A3 Adenosine Receptor Agonists: A Novel, Targeted Therapy
Fishman, P., Jacobson, K. A., Ochaion, A., Cohen, S., & Bar‐Yehuda, S. (2007) · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · doi:10.2174/187152207781369878 · Cited by 21
Self-citationGlutathione-Mediated Neuroprotective Effect of Purine Derivatives
Matsumura, N., & Aoyama, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713067 · Cited by 21
Progress on the development of Class A GPCR‐biased ligands
Morales, P., Scharf, M. M., Bermúdez, M., Egyed, A., Franco, R., Hansen, O. K., Jagerovic, N., Jakubík, J., Keserű, G. M., Kiss, D. J., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17301 · Cited by 23
Class A and C GPCR Dimers in Neurodegenerative Diseases
Moreira, I. S., Caniceiro, A. B., Bueschbell, B., & Schiedel, A. C. (2022) · Current Neuropharmacology · doi:10.2174/1570159x20666220327221830 · Cited by 20
The role of adenosine A1 receptor on immune cells
Zhong, L., Peng, Q., & Zeng, X. (2022) · Inflammation Research · doi:10.1007/s00011-022-01607-w · Cited by 24
“Adenosine is an endogenous small molecule that arises from the release of equilibrium transporters or from cell damage, but it is mainly produced by the hydrolysis of adenosine triphosphate through membrane-bound nucleotide enzymes: ectonucleoside triphosphate diphosphohydrolase-1 (CD39) and ecto-5′-nucleotidase (CD73…”
BackgroundAdenosine Receptors as Potential Therapeutic Analgesic Targets
Haddad, M., Cherchi, F., Alsalem, M., Al-saraireh, Y. M., & Madae’en, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713160 · Cited by 27
“Following the activation of these proteins, the stimulation of AC and increased cAMP synthesis are the highly significant intracellular events [15,49] that could stimulate cAMP-dependent kinase [120].”
BackgroundInfluential
Metadata
- Authors
- Jacobson, K. A., & Gao, Z.-G.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Jacobson, Kenneth A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-03
- Volume
- 5
- Issue
- 3
- Pages
- 247-264
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC3463109
- OpenAlex
- W1985598247
- Cited by
- 1,431
- References
- 215
- Citations by year
- 2026: 34 · 2025: 50 · 2024: 52 · 2023: 55 · 2022: 80 · 2021: 58 · 2020: 65 · 2019: 79 · 2018: 66 · 2017: 59 · 2016: 65 · 2015: 64 · 2014: 80 · 2013: 80 · 2012: 83
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases (Z01DK031117)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- adenosine receptors, adenosine receptor agonists, adenosine receptor antagonists, selective ligands, caffeine, cardiovascular disease, ischemic diseases, sleep disorders, inflammatory diseases, cancer, neurological disorders, drug development
- MeSH terms
- Animals, Disease, Drug Therapy, Humans, Ligands, Structure-Activity Relationship, Molecular Structure, Signal Transduction, Receptors, Purinergic P1, Purinergic P1 Receptor Agonists, Purinergic P1 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.